Fluidigm Opens Office in China, Strikes Services Pact with Ambry Genetics | GenomeWeb

This story was originally posted on April 20.

Fluidigm made two moves in recent weeks that put its integrated fluidic circuit biochips in direct competition with microarrays sold by vendors like Affymetrix, Agilent Technologies, Illumina, and Roche NimbleGen.

First, the South San Francisco, Calif.-based firm announced the establishment of a subsidiary in Shanghai, allowing it to directly serve customers from the same city in China where competitors like Affy and Illumina have their offices.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.